Tradjenta
Tradjenta

2.34
Helps the release of insulin after meals to keep blood sugar levels in a target range.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Linagliptin
Reference Brand
Linagliptin
Product Origin
Generic Alternative
Reference Manufacturer
Boehringer Ingelheim
Product Form
Tablet
Regulatory Classification
Rx
Primary Category
Diabetes Management
Product Category
DPP-4 Inhibitor
Pharmacological Class
Antidiabetic
Clinical Indications
Manufacturer Description
Intended for type 2 diabetes mellitus to manage blood glucose levels and support insulin response.
Mechanism of Action
Linagliptin inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). This prevents the degradation of incretin hormones, which increases insulin release and decreases glucagon levels in a glucose-dependent manner.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
24 hours
Contraindications
Hypersensitivity to linagliptin
Severe Adverse Events
Pancreatitis, Bullous pemphigoid, Severe arthralgia — requires immediate medical attention
Common Side Effects
Nasopharyngitis, Diarrhea, Headache
Uncommon Side Effects
Cough, Nausea, Elevated amylase
Drug Interactions
Alcohol, Rifampin, Digoxin, Insulin, Phenytoin
Pregnancy Safety Warnings
FDA Category B: Use only if clearly needed. Breastfeeding: Not known if excreted in milk.
Age Restrictions
Safety and efficacy in pediatric patients have not been established.
Storage Guidelines
Store at room temperature in a dry place.
Related Products
Trajenta, Januvia, Galvus
Information related to Tradjenta is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
How to access Analgesics Ireland - Naproxen Price Ireland